Transradial Intervention for Minimizing Bleeding Complications in Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 104, Issue 5 SUPPL., 2009, Pages 55C-59C

  Hamon, Martial ^a   Coutance, Guillaume ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG WITHDRAWAL; FEMORAL ARTERY; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIAL ARTERY; RISK FACTOR; RISK REDUCTION; VASCULAR ACCESS;

EID: 68749116637     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.023     Document Type: Article

References (31)

1. Doyle B.J., Ting H.H., Bell M.R., Lennon R.J., Mathew V., Singh M., Holmes D.R., and Rihal C. Major femoral bleeding complications after percutaneous coronary intervention. JACC Cardiovasc Interv 1 (2008) 202-209
2. Moscucci M., Fox K.A., Cannon C.P., Klein W., Lopez-Sendon J., Montalescot G., White K., and Goldberg R.J. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2005) 1815-1823
3. Segev A., Strauss B.H., Tan M., Constance C., Langer A., and Goodman S.G. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 150 (2005) 690-694
4. Rothman M. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nat Clin Pract Cardiovasc Med 2 (2005) 465-474
5. Jolly S.S., Amlani S., Hamon M., Yusuf S., and Mehta S.R. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 157 (2009) 132-140
6. Agostoni P., Biondi-Zoccai G.G., de Benedictis M.L., Rigattieri S., Turri M., Anselmi M., Vassanelli C., Zardini P., Louvard Y., and Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and interventional procedures. J Am Coll Cardiol 44 (2004) 349-356
7. Montalescot G., Ongen Z., Guindy R., Sousa A., Lu S.Z., Pahlajani D., Pellois A., and Vicaut E. Predictors of outcome in patients undergoing PCI: results of the RIVIERA study. Int J Cardiol 129 (2008) 379-387
8. Rao S.V., Ou F.S., Wang T.Y., Roe M.T., Brindis R., Rumsfeld J.S., and Peterson E.D. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention. JACC Cardiovasc Interv 1 (2008) 379-386
9. Brasselet C., Tassan S., Nazeyrollas P., Hamon M., and Metz D. Randomized comparison of femoral versus radial approach for percutaneous coronary intervention using abxicimab in acute myocardial infarction: results of the FARMI (Five French Arterial access with Reopro in Myocardial Infarction) Trial. Heart 93 (2007) 1556-1561
10. Steinhubl S.R., Kastrati A., and Berger P.B. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 154 (2007) 3-11
11. Kinnaird T.D., Stabile E., Mintz G., Lee C.W., Canos D.A., Gevokin N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
12. Rao S.V., Jollis J.G., Harrington R.A., Granger C.B., Newby L.K., Armstrong P.W., Moliterno D.J., Lindblad L., Pieper K., Topol E.J., Stamler J.S., and Califf R.M. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
13. Yang X., Alexander K.P., Chen A.Y., Roe M.T., Brindis R.G., Rao S.V., Gibler W.B., Ohman E.M., and Peterson E.D. The implications of blood transfusions for patients with non-ST segment elevation acute coronary syndromes: results from the crusade national quality improvement initiative. J Am Coll Cardiol 46 (2005) 1490-1495
14. Manoukian S., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., Dangas G.D., Lincoff M., White H.D., Moses J.W., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 49 (2007) 1362-1368
15. Hamon M., Filippi-Codaccioni E., Riddell J.W., and Le Page O. Prognostic impact of major bleeding in patients with acute coronary syndromes: a systematic review and meta-analysis. EuroIntervention 3 (2007) 400-408
16. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee To Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) 1-157
17. Bassand J., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernandez-Aviles F., Fox K.A., Hasdai D., Ohman E.M., Wallentin L., and Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society and Cardiology. Eur Heart J 28 (2008) 1598-1660
18. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., Joyner C., and Fox K.A. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
19. Ali A., Hashem M., Rosman H.S., Moser L., Rehan A., Davis T., Romanelli M., Lalonde T., Yamasaki H., Barbish B., et al. Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients. J Clin Pharmacol 44 (2004) 1328-1332
20. Eikelboom J.W., Shamir R.M., Anand S.S., Xie C., Kox K.A.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
21. Feit F., Voeltz M.D., Attubato M.J., Lincoff A.M., Chew D.P., Bittl J.A., Topol E.J., and Manoukian S.V. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 100 (2007) 1364-1369
22. Lenderink T., Boersma E., Ruzyllo W., Widimsky P., Ohman M., Armstrong P.W., Wallentin L., and Simoons M.L. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J 147 (2004) 865-873
23. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., Mahaffey K.W., Califf R.M., and Harrington R.A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
24. Stone G.W., McLaurin B.T., Cox D.A., Bertrand M.E., Lincoff A.M., Moses J.W., White H.D., Pocock S.J., Ware J.H., Feit F., et al. Prospective, randomized comparison of heparin plus glycoprotein IIb/IIIa inhibition and bivalirudin with or without glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: the ACUITY trial. N Engl J Med 355 (2006) 2203-2216
25. Nikolsky E., Mehran R., Halkin A., Aymong E.D., Mintz G.S., Lasic Z., Negoita M., Fahy M., Krieger S., Moussa I., et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 44 (2004) 1200-1209
26. Chase A.J., Fretz E.B., Warburton W.P., Klinke W.P., Carere R.G., Pi D., Berry B., and Hilton J.D. The association of arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L. study (Mortality benefit Of Reduced Transfusion after PCI via the Arm or Leg). Heart 94 (2008) 1019-1025
27. Hamon M., Rasmussen L.H., Manoukian S.V., Cequier A., Lincoff A.M., Rupprecht H.J., Gersh B.J., Mann T., Bertrand M.E., Mehran R., and Stone G.W. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention 5 (2009) 115-120
28. Hamon M., Steg G., Faxon D., Kerkar P., Rupprecht H.J., Tanguay J.F., Afzal R., and Yusuf S. Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: insights from OASIS-5 trial. Circulation 114 suppl II (2006) 552
29. Kiemeneij F., Laarman G.J., Oderkerken D., Slagboom T., and van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol 29 (1997) 1269-1275
30. Eccleshall S.C., Banks M., Carroll R., Jaumdally R., Fraser D., and Nolan J. Implementation of diagnostic and interventional transradial programme: resource and organizational implications. Heart 89 (2003) 561-562
31. Kinnaird T., Anderson, Hill J., and Thomas M. Bleeding during percutaneous intervention: tailoring the approach to minimize risk. Heart 95 (2008) 15-19